Last $8.95 USD
Change Today -0.13 / -1.43%
Volume 2.9M
ZIOP On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

ziopharm oncology inc (ZIOP) Snapshot

Open
$8.96
Previous Close
$9.08
Day High
$9.39
Day Low
$8.86
52 Week High
01/27/15 - $9.64
52 Week Low
10/8/14 - $2.31
Market Cap
919.3M
Average Volume 10 Days
4.3M
EPS TTM
$-0.30
Shares Outstanding
102.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ZIOPHARM ONCOLOGY INC (ZIOP)

ziopharm oncology inc (ZIOP) Related Bloomberg News

View More Bloomberg News

ziopharm oncology inc (ZIOP) Related Businessweek News

No Related Businessweek News Found

ziopharm oncology inc (ZIOP) Details

ZIOPHARM Oncology, Inc., a biopharmaceutical company, focuses on the discovery and development of cancer therapies that address unmet medical needs through synthetic biology. The company is employing novel gene expression and control technology to deliver DNA for the treatment of cancer. Its technology platform employs Intrexon Corporation’s RheoSwitch Therapeutic System platform to turn on and off, and modulate gene expression at the cancer site in order to improve the therapeutic index. This technology is being evaluated in Phase II clinical studies of the immune system cytokine interleukin-12 for the treatment of breast cancer and advanced melanoma. The company is also developing novel small molecules as potential cancer therapeutics. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.

43 Employees
Last Reported Date: 03/3/14

ziopharm oncology inc (ZIOP) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $600.0K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $230.3K
Chief Legal Officer, Executive Vice President...
Total Annual Compensation: $411.3K
Compensation as of Fiscal Year 2013.

ziopharm oncology inc (ZIOP) Key Developments

Intrexon Corporation and ZIOPHARM Oncology Announce Licensing Agreement with The University of Texas MD Anderson Cancer Center

Intrexon Corporation and ZIOPHARM Oncology announced a broad exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sublicensing agreement through MD Anderson for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies. The licensed technologies arise from the laboratory of Laurence Cooper, M.D., Ph.D., professor of pediatrics at MD Anderson and Perry Hackett, Ph.D., professor within the College of Biological Sciences at Minnesota. The Cooper and Hackett laboratories have pioneered the design and clinical investigation of novel chimeric antigen receptor (CAR) T cell therapies using non-viral gene integration platforms. MD Anderson has built on this technology to deliver patient-derived T cells, as well as innovative approaches to generating products for universal off-the-shelf applications. When combined with Intrexon’s technology suite and ZIOPHARM’s clinically tested RheoSwitch Therapeutic System® interleukin-12 modules, the resulting proprietary methods and technologies may help realize the promise of genetically modified CAR T cells by tightly controlling cell expansion and activation in the body, minimizing off-target effects and toxicity while maximizing therapeutic efficacy. Under the terms of the agreement, MD Anderson shall receive consideration of $100 million; $50 million from each Intrexon and ZIOPHARM, payable in shares of their respective common stock, as well as a commitment of $15 to $20 million annually over three years for researching and developing the technologies.

ZIOPHARM Oncology, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 03:30 PM

ZIOPHARM Oncology, Inc. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 03:30 PM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Jonathan J. Lewis, Chief Executive Officer and Director.

ZIOPHARM Oncology, Inc. Presents at Boston Biotech Conferences LLC's The East Meets West CEO conference, Jan-10-2015 02:20 PM

ZIOPHARM Oncology, Inc. Presents at Boston Biotech Conferences LLC's The East Meets West CEO conference, Jan-10-2015 02:20 PM. Venue: Four Seasons Hotel, 757 Market St, San Francisco, CA 94103. Speakers: Jonathan J. Lewis, Chief Executive Officer and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZIOP:US $8.95 USD -0.13

ZIOP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advaxis Inc $9.85 USD -0.29
Argos Therapeutics Inc $8.32 USD +0.34
Genocea Biosciences Inc $8.58 USD -0.01
GenVec Inc $3.39 USD +0.10
Inovio Pharmaceuticals Inc $8.34 USD -0.16
View Industry Companies
 

Industry Analysis

ZIOP

Industry Average

Valuation ZIOP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 729.0x
Price/Book 25.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 708.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZIOPHARM ONCOLOGY INC, please visit www.ziopharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.